Alzheimer's Disease and Gantenerumab: Trial Results and Future Directions State of Health

We delve into the results of the GRADUATE I and II trials, examining the impact of Gantenerumab, a human monoclonal antibody, on early Alzheimer's disease. We explore how its efficacy in reducing amyloid plaques failed to significantly alter the course of cognitive decline, while also discussing potential implications for future Alzheimer's disease treatments. Original article here.



ABOUT THE STATE OF HEALTH

The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠



FOLLOW US


Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠
Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠
Threads: ⁠⁠⁠⁠⁠⁠threads.net/@medzcool